NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
08/05/2026
Voltar para busca
Dado oficial do USPTO
BITE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
67
Atualização mais recente
02/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 35, 42
Data de depósito
26/12/2000
Data de registro
14/03/2006
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
08/05/2026
Última transação
02/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Primeiro uso
2001-11-00
Primeiro uso no comércio
2001-11-00
Código do desenho
1
Tipo de titular
16
Localização do titular
MUNICH, DE
Examinador
BLANDU, FLORENTINA
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
AMGEN RESEARCH (MUNICH) GMBH
MICROMET AG
Representantes
Elsa D. Lemoine Amgen Inc.
Classificação técnica
Classes Nice
Classe 5Classe 35Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicamentspolypeptidesparticularly antibodies and antibody derivativesfor use in the treatment of tumorous diseasesallergiesautoimmunityinflammationinfectious diseasesosteoporosisgraft versus host diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesin the form of intravenoussub-cutaneousintra-peritonealintra-muscular and aerosol therapies
Classe 35
Human and veterinary serviceslicensing of medicamentspolypeptidesparticularly antibodies and antibody derivativesfor use in the treatment of tumorous diseasesallergiesautoimmunityinflammationinfectious diseasesosteoporosisgraft versus host diseasetransplant rejectioncoronary heart diseasesminimal residual diseases; licensing of technology for the identification of tumorous diseasesallergiesautoimmunityinflammationinfectious diseasesosteoporosisgraft versus host diseasetransplant rejectioncoronary heart diseasesminimal residual diseasesfor the identification of expressed genesparticularly of abnormal expressed genesfor the analysis and identification of the gene expression pattern and eukaryotic cellsparticularly of single cells and cell culture linesparticularly of mammalian and human cellsparticularly of cells of microscopic small biopsies of animal and human tissuesof cells out of tissue samples prepared with laserof cells isolated with FACS or with receptor to ligand bindingof chemical fixed tissueof micrometastatic cellsof bone marrow cellsof samples of body fluidsparticularly from liquorbloodlymphurine or bowel movementof stem cellscloned single cells or differentiated stages from specific cells
Classe 42
Medical services; laboratory research in the field of polypeptidesparticularly antibodies and antibody derivatives; human and veterinary servicesproduct developmentin the field of medicamentspolypeptidesparticularly antibodies and antibody derivativesfor use in the treatment of tumorous diseasesallergiesautoimmunityinflammationinfectious diseasesosteoporosisgraft versus host diseasetransplant rejectioncoronary heart diseases and minimal residual diseases; product developmentin the field of diagnostic and testing apparatus and instruments for the identification of tumorous diseasesallergiesautoimmunityinflammationinfectious diseasesosteoporosisgraft versus host diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesfor the identification of expressed genesparticularly of abnormal expressed genesfor the analysis and identification of the gene expression pattern and eukaryotic cellsparticularly of single cells and cell culture linesparticularly of mammalian and human cellsparticularly of cells of microscopic small biopsies of animal and human tissuesof cells out of tissue samples prepared with laserof cells isolated with FACS or with receptor to ligand bindingof chemical fixed tissueof micrometastatic cellsof bone marrow cellsof samples of body fluidsparticularly from liquorbloodlymphurine or bowel movementof stem cellscloned single cells or differentiated stages from specific cells
Publicações
Histórico de despachos e eventos da marca no USPTO.
67 publicações encontradas
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
08/05/2026
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
08/05/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/05/2026
E89R
TEAS SECTION 8 & 9 RECEIVED
04/03/2026
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
14/03/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
29/04/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
29/04/2022
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
29/04/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
29/04/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
29/04/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
29/04/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
29/04/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/03/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/03/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/08/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/08/2018
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
28/06/2016
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
28/06/2016
9G8P
REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8
28/06/2016
8PRT
REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED
28/06/2016
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
28/06/2016
E89R
TEAS SECTION 8 & 9 RECEIVED
08/04/2016
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
23/03/2016
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
14/03/2015
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
02/04/2012
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
01/04/2012
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
31/03/2012
E815
TEAS SECTION 8 & 15 RECEIVED
01/03/2012
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
18/06/2011
R.PR
REGISTERED-PRINCIPAL REGISTER
14/03/2006
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
01/02/2006
ALIE
ASSIGNED TO LIE
01/02/2006
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
17/01/2006
SUPC
STATEMENT OF USE PROCESSING COMPLETE
27/12/2005
PAPER RECEIVED
05/12/2005
IUAF
USE AMENDMENT FILED
02/12/2005
EX3G
SOU EXTENSION 3 GRANTED
03/06/2005
EXT3
SOU EXTENSION 3 FILED
19/05/2005
EEXT
SOU TEAS EXTENSION RECEIVED
19/05/2005
EX2G
SOU EXTENSION 2 GRANTED
08/12/2004
EXT2
SOU EXTENSION 2 FILED
29/11/2004
EEXT
SOU TEAS EXTENSION RECEIVED
29/11/2004
EX1G
SOU EXTENSION 1 GRANTED
28/05/2004
CFIT
CASE FILE IN TICRS
26/05/2004
EXT1
SOU EXTENSION 1 FILED
19/05/2004
EEXT
SOU TEAS EXTENSION RECEIVED
19/05/2004
NOAM
NOA MAILED - SOU REQUIRED FROM APPLICANT
02/12/2003
PAPER RECEIVED
29/09/2003
PUBO
PUBLISHED FOR OPPOSITION
09/09/2003
NPUB
NOTICE OF PUBLICATION
20/08/2003
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
24/06/2003
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/05/2003
PAPER RECEIVED
22/05/2003
CNRT
NON-FINAL ACTION MAILED
06/01/2003
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/10/2002
PAPER RECEIVED
21/10/2002
CNRT
NON-FINAL ACTION MAILED
26/06/2002
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
09/06/2002
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/04/2002
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
10/04/2002
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/02/2002
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/02/2002
CNEA
EXAMINERS AMENDMENT MAILED
04/02/2002
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
29/11/2001
CNRT
NON-FINAL ACTION MAILED
06/06/2001
DOCK
ASSIGNED TO EXAMINER
17/05/2001
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BITE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.